Share Price and Basic Stock Data
Last Updated: December 19, 2025, 4:27 am
| PEG Ratio | 3.71 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Astrazeneca Pharma India Ltd has carved a notable niche in the pharmaceutical sector, reflecting a robust performance trajectory over recent years. For the financial year ending March 2025, the company reported sales of ₹1,716 Cr, a significant increase from ₹1,296 Cr in the previous year, highlighting a solid growth trend. The quarterly sales figures also support this narrative, with March 2024 sales recorded at ₹383 Cr, which rose to ₹388 Cr in June 2024, and further to ₹408 Cr by September 2024. The company’s ability to consistently grow its top line underscores a strong demand for its products, which is critical in a competitive industry. However, it’s worth noting that the growth rate appears to be tapering slightly, from a 29.2% year-on-year increase in FY 2024 to an estimated 27.5% in FY 2025. This slight deceleration could indicate market saturation or increased competition, factors that investors should monitor closely.
Profitability and Efficiency Metrics
When it comes to profitability, Astrazeneca Pharma India Ltd demonstrates a mixed bag of results. The company’s operating profit margin (OPM) stood at a commendable 15% as of the latest reporting period, yet it has fluctuated significantly over the past quarters—from a high of 23% in June 2023 to a concerning low of 5% in December 2023. This volatility raises questions about cost management and operational efficiency, particularly as expenses have risen sharply, from ₹225 Cr in March 2023 to ₹334 Cr in March 2024. The net profit for FY 2025 was reported at ₹116 Cr, down from ₹162 Cr in FY 2024, a decline that may reflect increased competition or rising input costs. Furthermore, the return on equity (ROE) at 15.02% indicates that while the company is generating profit, it may not be maximizing shareholder value as effectively as desired.
Balance Sheet Strength and Financial Ratios
Astrazeneca’s balance sheet exhibits a relatively strong position, with total reserves reported at ₹794 Cr against borrowings of only ₹35 Cr. This translates to a healthy debt-to-equity ratio, which suggests that the company is not overly reliant on debt to finance its operations. The interest coverage ratio (ICR) is impressive at 201.78x, indicating that the company can easily meet its interest obligations. However, the price-to-book value (P/BV) ratio sits at a lofty 27.93x, which may suggest that the stock is overvalued compared to its net asset value. Investors should tread carefully here, as such high valuations can lead to a correction if future growth does not meet expectations. Similarly, the current ratio of 1.91 indicates a comfortable liquidity position, allowing the company to cover its short-term liabilities without strain.
Shareholding Pattern and Investor Confidence
The shareholding structure of Astrazeneca Pharma India Ltd reveals a strong backing from promoters, who hold a steady 75% stake in the company. This level of promoter confidence can be reassuring for retail investors, suggesting a long-term commitment to the company’s growth. Foreign Institutional Investors (FIIs) have a modest stake of 2.74%, while Domestic Institutional Investors (DIIs) have increased their holdings to 5.26%. However, the public shareholding has declined to 17%, down from 20% in previous quarters, which might raise concerns regarding retail investor interest. The number of shareholders has also decreased from 45,619 in December 2022 to 32,914 in September 2025, indicating a potential consolidation in ownership that could affect market liquidity. This trend may signal a need for Astrazeneca to enhance its outreach and engagement with retail investors to maintain a vibrant shareholder base.
Outlook, Risks, and Final Insight
Looking ahead, Astrazeneca Pharma India Ltd appears poised for continued growth, but there are clear risks that investors should consider. The fluctuating profitability metrics, coupled with increasing operational costs, may pressure margins in the future. Additionally, the high P/BV ratio suggests that the market has high expectations for the company, which could lead to volatility if growth slows. On the flip side, the strong balance sheet and low debt levels provide a cushion against economic downturns. Investors might want to keep an eye on how Astrazeneca manages its costs and adapts to competitive pressures in the pharmaceutical landscape. Ultimately, while the company has solid fundamentals, the interplay between growth expectations and market realities will be crucial in shaping its future performance. Prudence is advised as one navigates the complexities of Astrazeneca’s stock, given the current valuation and market dynamics.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 116 | 235/84.3 | 32.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,239 Cr. | 389 | 479/192 | 87.8 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.8 Cr. | 45.5 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.2 Cr. | 32.9 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,006.85 Cr | 1,144.50 | 52.26 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 232 | 236 | 250 | 285 | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 |
| Expenses | 204 | 195 | 213 | 225 | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 |
| Operating Profit | 28 | 41 | 37 | 60 | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 |
| OPM % | 12% | 17% | 15% | 21% | 23% | 17% | 5% | 13% | 10% | 13% | 17% | 18% | 15% |
| Other Income | 4 | 7 | 7 | -32 | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 |
| Depreciation | 5 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 |
| Profit before tax | 27 | 44 | 39 | 23 | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 |
| Tax % | 26% | 26% | 26% | 26% | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% |
| Net Profit | 20 | 33 | 29 | 17 | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 |
| EPS in Rs | 8.06 | 13.02 | 11.72 | 6.91 | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 |
Last Updated: August 20, 2025, 1:25 pm
Below is a detailed analysis of the quarterly data for Astrazeneca Pharma India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 526.00 Cr.. The value appears strong and on an upward trend. It has increased from 480.00 Cr. (Mar 2025) to 526.00 Cr., marking an increase of 46.00 Cr..
- For Expenses, as of Jun 2025, the value is 445.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 394.00 Cr. (Mar 2025) to 445.00 Cr., marking an increase of 51.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 81.00 Cr.. The value appears to be declining and may need further review. It has decreased from 86.00 Cr. (Mar 2025) to 81.00 Cr., marking a decrease of 5.00 Cr..
- For OPM %, as of Jun 2025, the value is 15.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Mar 2025) to 15.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 17.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 75.00 Cr.. The value appears to be declining and may need further review. It has decreased from 78.00 Cr. (Mar 2025) to 75.00 Cr., marking a decrease of 3.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to 25.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 56.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Mar 2025) to 56.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 22.33. The value appears to be declining and may need further review. It has decreased from 23.30 (Mar 2025) to 22.33, marking a decrease of 0.97.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 474 | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,006 |
| Expenses | 487 | 528 | 547 | 506 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 1,687 |
| Operating Profit | -13 | -11 | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 320 |
| OPM % | -3% | -2% | 3% | 7% | 8% | 10% | 15% | 17% | 11% | 16% | 14% | 15% | 16% |
| Other Income | 23 | 6 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | -14 | 51 | -56 | -3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 10 | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 46 |
| Profit before tax | 0 | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 268 |
| Tax % | 0% | 9% | 44% | 41% | 25% | 37% | 27% | 26% | 26% | 26% | 26% | ||
| Net Profit | -1 | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 199 |
| EPS in Rs | -0.20 | -8.34 | 2.10 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 79.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 5% | 41% | 40% | 37% | 69% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2000.00% | 123.81% | 300.00% | 30.00% | 107.69% | 33.33% | 29.17% | -33.33% | 59.68% | 63.64% | -28.40% |
| Change in YoY Net Profit Growth (%) | 0.00% | 2123.81% | 176.19% | -270.00% | 77.69% | -74.36% | -4.17% | -62.50% | 93.01% | 3.96% | -92.03% |
Astrazeneca Pharma India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 16% |
| 3 Years: | 29% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 19% |
| 3 Years: | 43% |
| TTM: | 61% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 19% |
| 3 Years: | 44% |
| 1 Year: | 32% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 21% |
| 3 Years: | 23% |
| Last Year: | 24% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: December 4, 2025, 12:59 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 167 | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 | 794 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 9 | 7 | 5 | 36 | 35 |
| Other Liabilities | 244 | 261 | 247 | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 712 | 781 |
| Total Liabilities | 416 | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,615 |
| Fixed Assets | 94 | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 | 40 |
| CWIP | 9 | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 312 | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 | 1,575 |
| Total Assets | 416 | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,615 |
Below is a detailed analysis of the balance sheet data for Astrazeneca Pharma India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Reserves, as of Sep 2025, the value is 794.00 Cr.. The value appears strong and on an upward trend. It has increased from 765.00 Cr. (Mar 2025) to 794.00 Cr., marking an increase of 29.00 Cr..
- For Borrowings, as of Sep 2025, the value is 35.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 36.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 781.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 712.00 Cr. (Mar 2025) to 781.00 Cr., marking an increase of 69.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,615.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,518.00 Cr. (Mar 2025) to 1,615.00 Cr., marking an increase of 97.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 64.00 Cr. (Mar 2025) to 40.00 Cr., marking a decrease of 24.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,575.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,454.00 Cr. (Mar 2025) to 1,575.00 Cr., marking an increase of 121.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,615.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,518.00 Cr. (Mar 2025) to 1,615.00 Cr., marking an increase of 97.00 Cr..
Notably, the Reserves (794.00 Cr.) exceed the Borrowings (35.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -13.00 | -11.00 | 16.00 | 37.00 | 46.00 | 71.00 | 109.00 | 123.00 | 77.00 | 158.00 | 179.00 | 218.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 41 | 30 | 54 | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 | 39 |
| Inventory Days | 210 | 157 | 141 | 121 | 229 | 186 | 197 | 198 | 164 | 193 | 140 | 208 |
| Days Payable | 241 | 203 | 174 | 184 | 257 | 266 | 251 | 221 | 223 | 231 | 121 | 173 |
| Cash Conversion Cycle | 10 | -16 | 21 | -34 | 7 | -39 | -17 | 15 | -20 | 1 | 62 | 74 |
| Working Capital Days | -45 | -15 | -28 | -36 | -8 | -14 | -16 | -17 | -34 | -18 | 20 | 22 |
| ROCE % | -12% | -13% | 4% | 15% | 19% | 27% | 34% | 30% | 16% | 31% | 31% | 33% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 658,075 | 0.87 | 593.85 | 645,850 | 2025-12-08 07:42:13 | 1.89% |
| Bandhan Large & Mid Cap Fund | 96,791 | 0.68 | 87.34 | 88,791 | 2025-12-14 15:53:41 | 9.01% |
| Nippon India Pharma Fund | 62,568 | 0.67 | 56.46 | 11,561 | 2025-12-08 04:19:42 | 441.2% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 55,021 | 0.77 | 49.65 | N/A | N/A | N/A |
| ICICI Prudential Multicap Fund | 22,090 | 0.12 | 19.93 | N/A | N/A | N/A |
| Bandhan Aggressive Hybrid Fund | 18,833 | 1.14 | 16.99 | 18,044 | 2025-12-15 00:59:57 | 4.37% |
| Samco Flexi Cap Fund | 17,560 | 4.71 | 15.85 | 18,502 | 2025-12-14 15:53:41 | -5.09% |
| UTI MNC Fund | 15,177 | 0.48 | 13.7 | 14,461 | 2025-12-14 15:53:41 | 4.95% |
| Bandhan Large Cap Fund | 11,818 | 0.52 | 10.66 | 10,495 | 2025-12-14 11:20:50 | 12.61% |
| ICICI Prudential Smallcap Fund | 9,703 | 0.1 | 8.76 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 |
| Diluted EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 |
| Cash EPS (Rs.) | 62.29 | 70.58 | 46.22 | 31.42 | 45.37 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 |
| Dividend / Share (Rs.) | 32.00 | 24.00 | 16.00 | 10.00 | 2.00 |
| Revenue From Operations / Share (Rs.) | 686.52 | 518.21 | 401.19 | 322.24 | 325.42 |
| PBDIT / Share (Rs.) | 117.84 | 87.70 | 76.49 | 40.38 | 59.32 |
| PBIT / Share (Rs.) | 101.84 | 81.72 | 69.98 | 33.60 | 51.27 |
| PBT / Share (Rs.) | 62.54 | 87.82 | 53.64 | 33.22 | 50.84 |
| Net Profit / Share (Rs.) | 46.30 | 64.60 | 39.72 | 24.64 | 37.32 |
| PBDIT Margin (%) | 17.16 | 16.92 | 19.06 | 12.52 | 18.22 |
| PBIT Margin (%) | 14.83 | 15.77 | 17.44 | 10.42 | 15.75 |
| PBT Margin (%) | 9.11 | 16.94 | 13.37 | 10.30 | 15.62 |
| Net Profit Margin (%) | 6.74 | 12.46 | 9.89 | 7.64 | 11.46 |
| Return on Networth / Equity (%) | 15.02 | 22.68 | 16.86 | 12.04 | 20.45 |
| Return on Capital Employeed (%) | 31.23 | 28.34 | 29.11 | 16.03 | 27.20 |
| Return On Assets (%) | 7.62 | 14.98 | 10.08 | 7.19 | 12.04 |
| Asset Turnover Ratio (%) | 1.32 | 1.26 | 1.09 | 0.98 | 1.10 |
| Current Ratio (X) | 1.91 | 2.61 | 2.18 | 2.12 | 2.04 |
| Quick Ratio (X) | 1.13 | 1.97 | 1.68 | 1.70 | 1.51 |
| Inventory Turnover Ratio (X) | 4.42 | 0.61 | 0.51 | 0.59 | 0.59 |
| Dividend Payout Ratio (NP) (%) | 51.84 | 24.76 | 20.14 | 8.11 | 5.35 |
| Dividend Payout Ratio (CP) (%) | 38.52 | 22.66 | 17.30 | 6.36 | 4.40 |
| Earning Retention Ratio (%) | 48.16 | 75.24 | 79.86 | 91.89 | 94.65 |
| Cash Earning Retention Ratio (%) | 61.48 | 77.34 | 82.70 | 93.64 | 95.60 |
| Interest Coverage Ratio (X) | 201.78 | 182.71 | 303.52 | 106.25 | 136.06 |
| Interest Coverage Ratio (Post Tax) (X) | 146.57 | 121.90 | 222.46 | 65.84 | 86.60 |
| Enterprise Value (Cr.) | 20979.18 | 12795.16 | 7617.77 | 5940.17 | 7173.15 |
| EV / Net Operating Revenue (X) | 12.22 | 9.88 | 7.60 | 7.37 | 8.82 |
| EV / EBITDA (X) | 71.21 | 58.36 | 39.84 | 58.85 | 48.37 |
| MarketCap / Net Operating Revenue (X) | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 |
| Retention Ratios (%) | 48.15 | 75.23 | 79.85 | 91.88 | 94.64 |
| Price / BV (X) | 27.93 | 18.68 | 13.79 | 12.49 | 16.50 |
| Price / Net Operating Revenue (X) | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Astrazeneca Pharma India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For Diluted EPS (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For Cash EPS (Rs.), as of Mar 25, the value is 62.29. This value is within the healthy range. It has decreased from 70.58 (Mar 24) to 62.29, marking a decrease of 8.29.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 308.14. It has increased from 284.77 (Mar 24) to 308.14, marking an increase of 23.37.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 308.14. It has increased from 284.77 (Mar 24) to 308.14, marking an increase of 23.37.
- For Dividend / Share (Rs.), as of Mar 25, the value is 32.00. This value exceeds the healthy maximum of 3. It has increased from 24.00 (Mar 24) to 32.00, marking an increase of 8.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 686.52. It has increased from 518.21 (Mar 24) to 686.52, marking an increase of 168.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 117.84. This value is within the healthy range. It has increased from 87.70 (Mar 24) to 117.84, marking an increase of 30.14.
- For PBIT / Share (Rs.), as of Mar 25, the value is 101.84. This value is within the healthy range. It has increased from 81.72 (Mar 24) to 101.84, marking an increase of 20.12.
- For PBT / Share (Rs.), as of Mar 25, the value is 62.54. This value is within the healthy range. It has decreased from 87.82 (Mar 24) to 62.54, marking a decrease of 25.28.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For PBDIT Margin (%), as of Mar 25, the value is 17.16. This value is within the healthy range. It has increased from 16.92 (Mar 24) to 17.16, marking an increase of 0.24.
- For PBIT Margin (%), as of Mar 25, the value is 14.83. This value is within the healthy range. It has decreased from 15.77 (Mar 24) to 14.83, marking a decrease of 0.94.
- For PBT Margin (%), as of Mar 25, the value is 9.11. This value is below the healthy minimum of 10. It has decreased from 16.94 (Mar 24) to 9.11, marking a decrease of 7.83.
- For Net Profit Margin (%), as of Mar 25, the value is 6.74. This value is within the healthy range. It has decreased from 12.46 (Mar 24) to 6.74, marking a decrease of 5.72.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.02. This value is within the healthy range. It has decreased from 22.68 (Mar 24) to 15.02, marking a decrease of 7.66.
- For Return on Capital Employeed (%), as of Mar 25, the value is 31.23. This value is within the healthy range. It has increased from 28.34 (Mar 24) to 31.23, marking an increase of 2.89.
- For Return On Assets (%), as of Mar 25, the value is 7.62. This value is within the healthy range. It has decreased from 14.98 (Mar 24) to 7.62, marking a decrease of 7.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.32. It has increased from 1.26 (Mar 24) to 1.32, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.91. This value is within the healthy range. It has decreased from 2.61 (Mar 24) to 1.91, marking a decrease of 0.70.
- For Quick Ratio (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.97 (Mar 24) to 1.13, marking a decrease of 0.84.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.42. This value is within the healthy range. It has increased from 0.61 (Mar 24) to 4.42, marking an increase of 3.81.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 51.84. This value exceeds the healthy maximum of 50. It has increased from 24.76 (Mar 24) to 51.84, marking an increase of 27.08.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 38.52. This value is within the healthy range. It has increased from 22.66 (Mar 24) to 38.52, marking an increase of 15.86.
- For Earning Retention Ratio (%), as of Mar 25, the value is 48.16. This value is within the healthy range. It has decreased from 75.24 (Mar 24) to 48.16, marking a decrease of 27.08.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 61.48. This value is within the healthy range. It has decreased from 77.34 (Mar 24) to 61.48, marking a decrease of 15.86.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 201.78. This value is within the healthy range. It has increased from 182.71 (Mar 24) to 201.78, marking an increase of 19.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 146.57. This value is within the healthy range. It has increased from 121.90 (Mar 24) to 146.57, marking an increase of 24.67.
- For Enterprise Value (Cr.), as of Mar 25, the value is 20,979.18. It has increased from 12,795.16 (Mar 24) to 20,979.18, marking an increase of 8,184.02.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 12.22. This value exceeds the healthy maximum of 3. It has increased from 9.88 (Mar 24) to 12.22, marking an increase of 2.34.
- For EV / EBITDA (X), as of Mar 25, the value is 71.21. This value exceeds the healthy maximum of 15. It has increased from 58.36 (Mar 24) to 71.21, marking an increase of 12.85.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 12.54. This value exceeds the healthy maximum of 3. It has increased from 10.27 (Mar 24) to 12.54, marking an increase of 2.27.
- For Retention Ratios (%), as of Mar 25, the value is 48.15. This value is within the healthy range. It has decreased from 75.23 (Mar 24) to 48.15, marking a decrease of 27.08.
- For Price / BV (X), as of Mar 25, the value is 27.93. This value exceeds the healthy maximum of 3. It has increased from 18.68 (Mar 24) to 27.93, marking an increase of 9.25.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 12.54. This value exceeds the healthy maximum of 3. It has increased from 10.27 (Mar 24) to 12.54, marking an increase of 2.27.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astrazeneca Pharma India Ltd:
- Net Profit Margin: 6.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 31.23% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.02% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 146.57
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.13
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 98.2 (Industry average Stock P/E: 42.99)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Block N1, 12th Floor, Bengaluru Karnataka 560045 | comp.secy@astrazeneca.com http://www.astrazeneca.com/india |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Shilpa Divekar Nirula | Chairperson & Independent Director |
| Mr. Praveen Rao Akkinepally | Managing Director |
| Ms. Bhavana Agrawal | Executive Director |
| Ms. Sylvia Lorena Varela Ramon | Non Executive Director |
| Ms. Hooi Bien Chuah | Non Executive Director |
| Mr. Jesus Javier Diaz-Ropero Esteso | Non Executive Director |
| Ms. Revathy Ashok | Independent Director |
| Ms. Monica Widhani | Independent Director |
FAQ
What is the intrinsic value of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd's intrinsic value (as of 19 December 2025) is 5953.62 which is 34.41% lower the current market price of 9,077.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 22,692 Cr. market cap, FY2025-2026 high/low of 10,691/6,301, reserves of ₹794 Cr, and liabilities of 1,615 Cr.
What is the Market Cap of Astrazeneca Pharma India Ltd?
The Market Cap of Astrazeneca Pharma India Ltd is 22,692 Cr..
What is the current Stock Price of Astrazeneca Pharma India Ltd as on 19 December 2025?
The current stock price of Astrazeneca Pharma India Ltd as on 19 December 2025 is 9,077.
What is the High / Low of Astrazeneca Pharma India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Astrazeneca Pharma India Ltd stocks is 10,691/6,301.
What is the Stock P/E of Astrazeneca Pharma India Ltd?
The Stock P/E of Astrazeneca Pharma India Ltd is 98.2.
What is the Book Value of Astrazeneca Pharma India Ltd?
The Book Value of Astrazeneca Pharma India Ltd is 320.
What is the Dividend Yield of Astrazeneca Pharma India Ltd?
The Dividend Yield of Astrazeneca Pharma India Ltd is 0.35 %.
What is the ROCE of Astrazeneca Pharma India Ltd?
The ROCE of Astrazeneca Pharma India Ltd is 33.4 %.
What is the ROE of Astrazeneca Pharma India Ltd?
The ROE of Astrazeneca Pharma India Ltd is 23.6 %.
What is the Face Value of Astrazeneca Pharma India Ltd?
The Face Value of Astrazeneca Pharma India Ltd is 2.00.